WO2008058448A1 - Dérivés de pyrroline agissant contre les cellules libérant le facteur de nécrose tumorale, procédés de préparation et utilisations associés - Google Patents
Dérivés de pyrroline agissant contre les cellules libérant le facteur de nécrose tumorale, procédés de préparation et utilisations associés Download PDFInfo
- Publication number
- WO2008058448A1 WO2008058448A1 PCT/CN2007/002965 CN2007002965W WO2008058448A1 WO 2008058448 A1 WO2008058448 A1 WO 2008058448A1 CN 2007002965 W CN2007002965 W CN 2007002965W WO 2008058448 A1 WO2008058448 A1 WO 2008058448A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrocarbyl
- formula
- compound
- hydrocarbon group
- hydrocarbon
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title description 24
- 102000003390 tumor necrosis factor Human genes 0.000 title description 24
- 150000003236 pyrrolines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 145
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 33
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 25
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 337
- 239000002904 solvent Substances 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 49
- -1 CF 3 Inorganic materials 0.000 claims description 36
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 24
- 239000004215 Carbon black (E152) Substances 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 23
- 229930195733 hydrocarbon Natural products 0.000 claims description 23
- 150000002430 hydrocarbons Chemical class 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 230000005856 abnormality Effects 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 230000035939 shock Effects 0.000 claims description 9
- 201000004792 malaria Diseases 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 206010025135 lupus erythematosus Diseases 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 206010006895 Cachexia Diseases 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 5
- 230000000004 hemodynamic effect Effects 0.000 claims description 5
- 201000008383 nephritis Diseases 0.000 claims description 5
- 229930192474 thiophene Natural products 0.000 claims description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 206010062207 Mycobacterial infection Diseases 0.000 claims description 4
- 208000001388 Opportunistic Infections Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims description 4
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 claims description 3
- 208000027496 Behcet disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010015150 Erythema Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010024229 Leprosy Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 231100000321 erythema Toxicity 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 208000013076 thyroid tumor Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 150000002923 oximes Chemical class 0.000 claims 2
- PFJOTFSIBVZGPK-UHFFFAOYSA-N 1-ethyl-2-methylhydrazine Chemical compound CCNNC PFJOTFSIBVZGPK-UHFFFAOYSA-N 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000003928 nasal cavity Anatomy 0.000 claims 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 150000004677 hydrates Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 77
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
- 239000007787 solid Substances 0.000 description 64
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 59
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 239000012265 solid product Substances 0.000 description 57
- 238000002474 experimental method Methods 0.000 description 52
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 51
- 238000005160 1H NMR spectroscopy Methods 0.000 description 40
- 229920006395 saturated elastomer Polymers 0.000 description 38
- 238000003756 stirring Methods 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 30
- 238000005481 NMR spectroscopy Methods 0.000 description 28
- 238000001035 drying Methods 0.000 description 28
- 239000012044 organic layer Substances 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 27
- 238000004440 column chromatography Methods 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 238000000746 purification Methods 0.000 description 21
- 229940017219 methyl propionate Drugs 0.000 description 20
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- FGCXSFRGPCUBPW-UHFFFAOYSA-N 3-amino-3-(3,4-dimethoxyphenyl)propanoic acid Chemical compound COC1=CC=C(C(N)CC(O)=O)C=C1OC FGCXSFRGPCUBPW-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 17
- 238000001816 cooling Methods 0.000 description 16
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 11
- 229940125773 compound 10 Drugs 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 229940126639 Compound 33 Drugs 0.000 description 9
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 9
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- 229940126214 compound 3 Drugs 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 238000003760 magnetic stirring Methods 0.000 description 8
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 8
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- 229940126540 compound 41 Drugs 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019260 propionic acid Nutrition 0.000 description 6
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940125797 compound 12 Drugs 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 5
- ZWWLLYJRPKYTDF-UHFFFAOYSA-N thiophene-3,4-dicarboxylic acid Chemical compound OC(=O)C1=CSC=C1C(O)=O ZWWLLYJRPKYTDF-UHFFFAOYSA-N 0.000 description 5
- PGNOUOYYXIUSSN-UHFFFAOYSA-N 3-(3-methoxy-4-phenylmethoxyphenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound COC1=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C1OCC1=CC=CC=C1 PGNOUOYYXIUSSN-UHFFFAOYSA-N 0.000 description 4
- LNJZYVQBKBGDSR-UHFFFAOYSA-N 3-amino-3-(3-ethoxy-4-methoxyphenyl)propanenitrile Chemical compound CCOC1=CC(C(N)CC#N)=CC=C1OC LNJZYVQBKBGDSR-UHFFFAOYSA-N 0.000 description 4
- JTQCVSLHXUMLGF-UHFFFAOYSA-N 3-azaniumyl-3-(3-ethoxy-4-methoxyphenyl)propanoate Chemical compound CCOC1=CC(C([NH3+])CC([O-])=O)=CC=C1OC JTQCVSLHXUMLGF-UHFFFAOYSA-N 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- CULNJCKWLSGTIW-UHFFFAOYSA-N ethyl 3-amino-3-(3-ethoxy-4-methoxyphenyl)propanoate Chemical compound CCOC(=O)CC(N)C1=CC=C(OC)C(OCC)=C1 CULNJCKWLSGTIW-UHFFFAOYSA-N 0.000 description 4
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical group CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- OXKUGIFNIUUKAW-UHFFFAOYSA-N n,n-dimethylformamide;hydrazine Chemical compound NN.CN(C)C=O OXKUGIFNIUUKAW-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- JYVNEDCTCVPCFO-UHFFFAOYSA-N tert-butyl 3-amino-2-(3-ethoxy-4-methoxyphenyl)-4-oxobutanoate Chemical compound CCOC1=CC(C(C(N)C=O)C(=O)OC(C)(C)C)=CC=C1OC JYVNEDCTCVPCFO-UHFFFAOYSA-N 0.000 description 4
- FQGSSNNXSOFMTD-UHFFFAOYSA-N tert-butyl 4-amino-2-(3-ethoxy-4-methoxyphenyl)-3-hydroxy-2-methylbutanoate Chemical compound CCOC1=CC(C(C)(C(O)CN)C(=O)OC(C)(C)C)=CC=C1OC FQGSSNNXSOFMTD-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 3
- QRJAJYXQSFQBPD-UHFFFAOYSA-N 1-(3-ethoxy-4-methoxyphenyl)-3-methoxypropan-1-amine Chemical compound CCOC1=CC(C(N)CCOC)=CC=C1OC QRJAJYXQSFQBPD-UHFFFAOYSA-N 0.000 description 3
- ISLJZPNQCGEGFM-UHFFFAOYSA-N 1-(3-methoxy-4-phenylmethoxyphenyl)-N',N'-dimethylpropane-1,3-diamine Chemical compound COC=1C=C(C=CC=1OCC1=CC=CC=C1)C(CCN(C)C)N ISLJZPNQCGEGFM-UHFFFAOYSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- CIHZUJHXJUTVQR-UHFFFAOYSA-N 3-amino-3-(3,4-dimethoxyphenyl)propanenitrile Chemical compound COC1=CC=C(C(N)CC#N)C=C1OC CIHZUJHXJUTVQR-UHFFFAOYSA-N 0.000 description 3
- RECWEJVIZCZBGO-UHFFFAOYSA-N 3-amino-3-(3-cyclopentyloxy-4-methoxyphenyl)propanenitrile Chemical compound COC1=CC=C(C(N)CC#N)C=C1OC1CCCC1 RECWEJVIZCZBGO-UHFFFAOYSA-N 0.000 description 3
- OJRXGWPSOSXIDE-UHFFFAOYSA-N 3-amino-3-(3-ethoxy-4-methoxyphenyl)propan-1-ol Chemical compound CCOC1=CC(C(N)CCO)=CC=C1OC OJRXGWPSOSXIDE-UHFFFAOYSA-N 0.000 description 3
- AWLKHBQVASSZPM-UHFFFAOYSA-N 3-amino-3-(3-methoxy-4-phenylmethoxyphenyl)propanenitrile Chemical compound COC1=CC(C(N)CC#N)=CC=C1OCC1=CC=CC=C1 AWLKHBQVASSZPM-UHFFFAOYSA-N 0.000 description 3
- XTSSUEXZEBKVEZ-UHFFFAOYSA-N 3-amino-3-(4-ethoxy-3-methoxyphenyl)propan-1-ol Chemical compound CCOC1=CC=C(C(N)CCO)C=C1OC XTSSUEXZEBKVEZ-UHFFFAOYSA-N 0.000 description 3
- AENSMQWHQVCMEB-UHFFFAOYSA-N 3-amino-3-(4-ethoxy-3-methoxyphenyl)propanenitrile Chemical compound CCOC1=CC=C(C(N)CC#N)C=C1OC AENSMQWHQVCMEB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010053879 Sepsis syndrome Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 229940127573 compound 38 Drugs 0.000 description 3
- 229940125900 compound 59 Drugs 0.000 description 3
- WUESWDIHTKHGQA-UHFFFAOYSA-N cyclohexylurea Chemical compound NC(=O)NC1CCCCC1 WUESWDIHTKHGQA-UHFFFAOYSA-N 0.000 description 3
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 3
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 3
- JNTCGRCDMCFMET-UHFFFAOYSA-N ethyl 3-amino-3-(4-ethoxy-3-methoxyphenyl)propanoate Chemical compound CCOC(=O)CC(N)C1=CC=C(OCC)C(OC)=C1 JNTCGRCDMCFMET-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- VSDUZFOSJDMAFZ-VIFPVBQESA-N methyl L-phenylalaninate Chemical compound COC(=O)[C@@H](N)CC1=CC=CC=C1 VSDUZFOSJDMAFZ-VIFPVBQESA-N 0.000 description 3
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- ZCXSYKJCSVECJL-UHFFFAOYSA-N tert-butyl 4-(iodomethyl)thiophene-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CSC=C1CI ZCXSYKJCSVECJL-UHFFFAOYSA-N 0.000 description 3
- WVCAHNNJDWMRQI-UHFFFAOYSA-N tert-butyl 4-amino-2-(3-ethoxy-4-methoxyphenyl)-2-methyl-3-oxobutanoate Chemical compound CCOC1=CC(C(C)(C(=O)CN)C(=O)OC(C)(C)C)=CC=C1OC WVCAHNNJDWMRQI-UHFFFAOYSA-N 0.000 description 3
- PULJJIXMCNKRLX-UHFFFAOYSA-N tert-butyl n-[1-(3-ethoxy-4-methoxyphenyl)-3-hydroxypropyl]carbamate Chemical compound CCOC1=CC(C(CCO)NC(=O)OC(C)(C)C)=CC=C1OC PULJJIXMCNKRLX-UHFFFAOYSA-N 0.000 description 3
- OOPXKQQQENGHPQ-UHFFFAOYSA-N tert-butyl n-[3-hydroxy-1-(3-methoxy-4-phenylmethoxyphenyl)propyl]carbamate Chemical compound COC1=CC(C(CCO)NC(=O)OC(C)(C)C)=CC=C1OCC1=CC=CC=C1 OOPXKQQQENGHPQ-UHFFFAOYSA-N 0.000 description 3
- JSLBLMYJYPZTEB-UHFFFAOYSA-N thiophene-3,4-dicarbonitrile Chemical compound N#CC1=CSC=C1C#N JSLBLMYJYPZTEB-UHFFFAOYSA-N 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- QVUNLLWWQKILLR-UHFFFAOYSA-N 2-nitrothiophene-3,4-dicarboxylic acid Chemical compound OC(=O)C1=CSC([N+]([O-])=O)=C1C(O)=O QVUNLLWWQKILLR-UHFFFAOYSA-N 0.000 description 2
- SVGZHVAYLRLBLW-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)-3-(3-methoxy-4-phenylmethoxyphenyl)propanamide Chemical compound COC1=CC(C(CC(N)=O)N2C(C3=CC=CC=C3C2=O)=O)=CC=C1OCC1=CC=CC=C1 SVGZHVAYLRLBLW-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- PLGHQLWEKSZSMK-UHFFFAOYSA-N 3-amino-3-(3-ethoxy-4-methoxyphenyl)butan-2-ol Chemical compound CCOC1=CC(C(C)(N)C(C)O)=CC=C1OC PLGHQLWEKSZSMK-UHFFFAOYSA-N 0.000 description 2
- AEPQLLSJPRUPAM-UHFFFAOYSA-N 3-amino-3-(3-ethoxy-4-methoxyphenyl)butan-2-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC1=CC(C(C)(N)C(C)=O)=CC=C1OC AEPQLLSJPRUPAM-UHFFFAOYSA-N 0.000 description 2
- HQBBROYIMMEMLL-UHFFFAOYSA-N 3-amino-3-(3-methoxy-4-phenylmethoxyphenyl)-n-methylpropanamide Chemical compound COC1=CC(C(N)CC(=O)NC)=CC=C1OCC1=CC=CC=C1 HQBBROYIMMEMLL-UHFFFAOYSA-N 0.000 description 2
- YMZQVUULKDEQFY-UHFFFAOYSA-N 3-amino-3-(3-methoxy-4-phenylmethoxyphenyl)-n-phenylpropanamide Chemical compound COC1=CC(C(N)CC(=O)NC=2C=CC=CC=2)=CC=C1OCC1=CC=CC=C1 YMZQVUULKDEQFY-UHFFFAOYSA-N 0.000 description 2
- VSOZEPFSOZWWOY-UHFFFAOYSA-N 3-amino-3-(3-methoxy-4-phenylmethoxyphenyl)propanamide Chemical compound COC1=CC(C(N)CC(N)=O)=CC=C1OCC1=CC=CC=C1 VSOZEPFSOZWWOY-UHFFFAOYSA-N 0.000 description 2
- ONRMTTMHPXYGFC-UHFFFAOYSA-N 3-amino-n-benzyl-3-(3-ethoxy-4-methoxyphenyl)propanamide Chemical compound C1=C(OC)C(OCC)=CC(C(N)CC(=O)NCC=2C=CC=CC=2)=C1 ONRMTTMHPXYGFC-UHFFFAOYSA-N 0.000 description 2
- ZGEDAOSSJYQGDT-UHFFFAOYSA-N 3-amino-n-ethyl-3-(3-methoxy-4-phenylmethoxyphenyl)propanamide Chemical compound COC1=CC(C(N)CC(=O)NCC)=CC=C1OCC1=CC=CC=C1 ZGEDAOSSJYQGDT-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- CZRCFAOMWRAFIC-UHFFFAOYSA-N 5-(tetradecyloxy)-2-furoic acid Chemical compound CCCCCCCCCCCCCCOC1=CC=C(C(O)=O)O1 CZRCFAOMWRAFIC-UHFFFAOYSA-N 0.000 description 2
- IPEMCIBPDYCJLO-UHFFFAOYSA-N 5-[(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)methyl]-n-(2,4,6-trimethoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC(OC)=CC(OC)=C1NC(=O)C(O1)=CC=C1CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C IPEMCIBPDYCJLO-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- LGPSGLLMSLPNJL-UHFFFAOYSA-N N',N'-diethyl-1-(3-methoxy-4-phenylmethoxyphenyl)propane-1,3-diamine Chemical compound COC=1C=C(C=CC=1OCC1=CC=CC=C1)C(CCN(CC)CC)N LGPSGLLMSLPNJL-UHFFFAOYSA-N 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- 208000010505 Nose Neoplasms Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 201000010001 Silicosis Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 206010043515 Throat cancer Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- DPDHEFCLHFWWJB-UHFFFAOYSA-N methyl 3-amino-3-(3,4-dimethoxyphenyl)propanoate Chemical compound COC(=O)CC(N)C1=CC=C(OC)C(OC)=C1 DPDHEFCLHFWWJB-UHFFFAOYSA-N 0.000 description 2
- NJWNMPYFTMYYDX-UHFFFAOYSA-N methyl 3-amino-3-(3-ethoxy-4-methoxyphenyl)propanoate Chemical compound CCOC1=CC(C(N)CC(=O)OC)=CC=C1OC NJWNMPYFTMYYDX-UHFFFAOYSA-N 0.000 description 2
- YZDOQRZXTDHHNB-UHFFFAOYSA-N methyl 3-amino-3-(4-methoxy-3-propoxyphenyl)propanoate Chemical compound CCCOC1=CC(C(N)CC(=O)OC)=CC=C1OC YZDOQRZXTDHHNB-UHFFFAOYSA-N 0.000 description 2
- KZOZDDREXRFZJK-UHFFFAOYSA-N methyl 3-amino-3-pyridin-4-ylpropanoate Chemical compound COC(=O)CC(N)C1=CC=NC=C1 KZOZDDREXRFZJK-UHFFFAOYSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000037830 nasal cancer Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- HXFNMFNGYBYJBT-UHFFFAOYSA-N tert-butyl 4-amino-2-(3-ethoxy-4-methoxyphenyl)-4-hydroxybutanoate Chemical compound CCOC1=CC(C(CC(N)O)C(=O)OC(C)(C)C)=CC=C1OC HXFNMFNGYBYJBT-UHFFFAOYSA-N 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- YNVOMSDITJMNET-UHFFFAOYSA-N thiophene-3-carboxylic acid Chemical compound OC(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical group C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical group S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- VRPSOXSTRRDMAA-BWLLBFHSSA-N (4R,4aR,7S,7aR,12bS)-3,8a-dimethyl-1,2,4,4a,7,7a,9,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound O[C@H]([C@@H]1OC2(C)C(O)C=C3)C=C[C@H]4[C@]5([H])N(C)CC[C@@]41C2=C3C5 VRPSOXSTRRDMAA-BWLLBFHSSA-N 0.000 description 1
- IFDZZSXEPSSHNC-ONEGZZNKSA-N (ne)-n-propylidenehydroxylamine Chemical compound CC\C=N\O IFDZZSXEPSSHNC-ONEGZZNKSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- DSNNEDPNIHLXNS-UHFFFAOYSA-N 1-[3-(2,5-dihydrothiophen-2-yl)-3-(3-methoxy-4-phenylmethoxyphenyl)propyl]piperidine Chemical compound COC1=CC(C(CCN2CCCCC2)C2C=CCS2)=CC=C1OCC1=CC=CC=C1 DSNNEDPNIHLXNS-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- UVAJCDOUVGWEFK-UHFFFAOYSA-N 1-methyl-2,3-dihydropyrrole Chemical compound CN1CCC=C1 UVAJCDOUVGWEFK-UHFFFAOYSA-N 0.000 description 1
- JEXYCADTAFPULN-UHFFFAOYSA-N 1-propylsulfonylpropane Chemical compound CCCS(=O)(=O)CCC JEXYCADTAFPULN-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- VGKLVWTVCUDISO-UHFFFAOYSA-N 3,4-dibromothiophene Chemical compound BrC1=CSC=C1Br VGKLVWTVCUDISO-UHFFFAOYSA-N 0.000 description 1
- ATSIJEKGXKMMOW-UHFFFAOYSA-N 3-(2,5-dihydrothiophen-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propan-1-ol Chemical compound C1=C(OC)C(OCC)=CC(C(CCO)C2C=CCS2)=C1 ATSIJEKGXKMMOW-UHFFFAOYSA-N 0.000 description 1
- FVNPJPVIIUTNRR-UHFFFAOYSA-N 3-(2,5-dihydrothiophen-2-yl)-3-(3-methoxy-4-phenylmethoxyphenyl)-1-piperidin-1-ylpropan-1-one Chemical compound COC1=CC(C(CC(=O)N2CCCCC2)C2C=CCS2)=CC=C1OCC1=CC=CC=C1 FVNPJPVIIUTNRR-UHFFFAOYSA-N 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- GKPXSGPDRIUIAD-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(N)=O)N1C(=O)C2=CC=CC=C2C1=O GKPXSGPDRIUIAD-UHFFFAOYSA-N 0.000 description 1
- WQNMCPJDFMJEEN-UHFFFAOYSA-N 3-(4-ethoxy-3-methoxyphenyl)propanamide Chemical compound CCOC1=CC=C(CCC(N)=O)C=C1OC WQNMCPJDFMJEEN-UHFFFAOYSA-N 0.000 description 1
- RGICSXKVRUULGR-UHFFFAOYSA-N 3-amino-3-(3-cyclopentyloxy-4-methoxyphenyl)propanoic acid Chemical compound COC1=CC=C(C(N)CC(O)=O)C=C1OC1CCCC1 RGICSXKVRUULGR-UHFFFAOYSA-N 0.000 description 1
- VJANWWLOYWLUTK-UHFFFAOYSA-N 3-amino-3-(3-methoxy-4-propan-2-yloxyphenyl)propanoic acid Chemical compound COC1=CC(C(N)CC(O)=O)=CC=C1OC(C)C VJANWWLOYWLUTK-UHFFFAOYSA-N 0.000 description 1
- OOKYWAXNZYBZER-UHFFFAOYSA-N 3-amino-3-(4-ethoxy-3-methoxyphenyl)propanoic acid Chemical compound CCOC1=CC=C(C(N)CC(O)=O)C=C1OC OOKYWAXNZYBZER-UHFFFAOYSA-N 0.000 description 1
- KQWGZZKVZHAPOR-UHFFFAOYSA-N 3-amino-3-(4-methoxy-3-phenylmethoxyphenyl)propanoic acid Chemical compound COC1=CC=C(C(N)CC(O)=O)C=C1OCC1=CC=CC=C1 KQWGZZKVZHAPOR-UHFFFAOYSA-N 0.000 description 1
- FVZYNNDWPRWCEJ-UHFFFAOYSA-N 3-amino-3-(4-methoxy-3-propan-2-yloxyphenyl)propanoic acid Chemical compound NC(CC(=O)O)C1=CC(=C(C=C1)OC)OC(C)C FVZYNNDWPRWCEJ-UHFFFAOYSA-N 0.000 description 1
- ZFJXLKNOJGNNIR-UHFFFAOYSA-N 3-amino-3-(4-methoxy-3-propoxyphenyl)propanoic acid Chemical compound NC(CC(=O)O)C1=CC(=C(C=C1)OC)OCCC ZFJXLKNOJGNNIR-UHFFFAOYSA-N 0.000 description 1
- VODMAXQPPKRFPS-UHFFFAOYSA-N 3-amino-3-(4-phenylmethoxyphenyl)propanoic acid Chemical compound C1=CC(C(CC(O)=O)N)=CC=C1OCC1=CC=CC=C1 VODMAXQPPKRFPS-UHFFFAOYSA-N 0.000 description 1
- UJOYFRCOTPUKAK-UHFFFAOYSA-N 3-ammonio-3-phenylpropanoate Chemical compound [O-]C(=O)CC([NH3+])C1=CC=CC=C1 UJOYFRCOTPUKAK-UHFFFAOYSA-N 0.000 description 1
- ZTBVHMNMNSGPKJ-UHFFFAOYSA-N 3-azaniumyl-3-(3-methoxy-4-phenylmethoxyphenyl)propanoate Chemical compound COC1=CC(C(N)CC(O)=O)=CC=C1OCC1=CC=CC=C1 ZTBVHMNMNSGPKJ-UHFFFAOYSA-N 0.000 description 1
- PXTDRMAWCZZRKO-UHFFFAOYSA-N 3-azaniumyl-3-(3-methylthiophen-2-yl)propanoate Chemical compound CC=1C=CSC=1C(N)CC(O)=O PXTDRMAWCZZRKO-UHFFFAOYSA-N 0.000 description 1
- BXGDBHAMTMMNTO-UHFFFAOYSA-N 3-azaniumyl-3-(4-chlorophenyl)propanoate Chemical compound OC(=O)CC(N)C1=CC=C(Cl)C=C1 BXGDBHAMTMMNTO-UHFFFAOYSA-N 0.000 description 1
- BSQKBHXYEKVKMN-UHFFFAOYSA-N 3-methylthiophene-2-carbaldehyde Chemical compound CC=1C=CSC=1C=O BSQKBHXYEKVKMN-UHFFFAOYSA-N 0.000 description 1
- SIPCFXFCVTUAID-UHFFFAOYSA-N 3-nitrothiophene Chemical compound [O-][N+](=O)C=1C=CSC=1 SIPCFXFCVTUAID-UHFFFAOYSA-N 0.000 description 1
- ILUREHFIZDLQTL-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonyl]thiophene-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)C1=CSC=C1C(O)=O ILUREHFIZDLQTL-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- DPZUJSIPWMIEML-UHFFFAOYSA-N C(=O)(OCC1=CC=CC=C1)C(C(C=O)N)C1=CC(=C(C=C1)OC)OCC Chemical compound C(=O)(OCC1=CC=CC=C1)C(C(C=O)N)C1=CC(=C(C=C1)OC)OCC DPZUJSIPWMIEML-UHFFFAOYSA-N 0.000 description 1
- FMJFWTUZFFFBNC-UHFFFAOYSA-N C(C)C(C(=O)N)(C)CC.NN Chemical group C(C)C(C(=O)N)(C)CC.NN FMJFWTUZFFFBNC-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- XPOLVFHFMDERBJ-UHFFFAOYSA-N COC1=CC(C(CC(=O)NC=2C=CC=CC=2)N2C(C3=CC=CC=C3C2=O)=O)=CC=C1OCC1=CC=CC=C1 Chemical group COC1=CC(C(CC(=O)NC=2C=CC=CC=2)N2C(C3=CC=CC=C3C2=O)=O)=CC=C1OCC1=CC=CC=C1 XPOLVFHFMDERBJ-UHFFFAOYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- AEFLONBTGZFSGQ-VKHMYHEASA-N L-isoglutamine Chemical compound NC(=O)[C@@H](N)CCC(O)=O AEFLONBTGZFSGQ-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- ZAHXYMFVNNUHCP-UHFFFAOYSA-N Naphazoline nitrate Chemical group O[N+]([O-])=O.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 ZAHXYMFVNNUHCP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- GYJKKRAJHCHMDX-UHFFFAOYSA-N O=C1C2=CC=CC=C2C(=O)N1C(CC(=O)NC)C(C=C1OC)=CC=C1OCC1=CC=CC=C1 Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CC(=O)NC)C(C=C1OC)=CC=C1OCC1=CC=CC=C1 GYJKKRAJHCHMDX-UHFFFAOYSA-N 0.000 description 1
- FXDOPPCPWGHSBC-UHFFFAOYSA-N O=C1C2=CC=CC=C2C(=O)N1C(CC(=O)NCC)C(C=C1OC)=CC=C1OCC1=CC=CC=C1 Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(CC(=O)NCC)C(C=C1OC)=CC=C1OCC1=CC=CC=C1 FXDOPPCPWGHSBC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical group C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000004706 cardiovascular dysfunction Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- BHFLUDRTVIDDOR-QMMMGPOBSA-N methyl (2s)-2-amino-2-phenylacetate Chemical compound COC(=O)[C@@H](N)C1=CC=CC=C1 BHFLUDRTVIDDOR-QMMMGPOBSA-N 0.000 description 1
- UDHNWYRORFIKCM-UHFFFAOYSA-N methyl 3-amino-3-(3-cyclopentyloxy-4-methoxyphenyl)propanoate Chemical compound COC(=O)CC(N)C1=CC=C(OC)C(OC2CCCC2)=C1 UDHNWYRORFIKCM-UHFFFAOYSA-N 0.000 description 1
- QXRTYOPJXUEQFC-UHFFFAOYSA-N methyl 3-amino-3-(3-methoxy-4-phenylmethoxyphenyl)propanoate Chemical compound COC1=CC(C(N)CC(=O)OC)=CC=C1OCC1=CC=CC=C1 QXRTYOPJXUEQFC-UHFFFAOYSA-N 0.000 description 1
- APYAILFUTXOAMX-UHFFFAOYSA-N methyl 3-amino-3-(3-methoxy-4-propan-2-yloxyphenyl)propanoate Chemical compound COC(=O)CC(N)C1=CC=C(OC(C)C)C(OC)=C1 APYAILFUTXOAMX-UHFFFAOYSA-N 0.000 description 1
- MWUPULFXWPZBGU-UHFFFAOYSA-N methyl 3-amino-3-(3-methylthiophen-2-yl)propanoate Chemical compound COC(=O)CC(N)C=1SC=CC=1C MWUPULFXWPZBGU-UHFFFAOYSA-N 0.000 description 1
- OWKAREWNOLQNOG-UHFFFAOYSA-N methyl 3-amino-3-(4-chlorophenyl)propanoate Chemical compound COC(=O)CC(N)C1=CC=C(Cl)C=C1 OWKAREWNOLQNOG-UHFFFAOYSA-N 0.000 description 1
- MQUATXVULWXAAN-UHFFFAOYSA-N methyl 3-amino-3-(4-cyclopentyloxy-3-methoxyphenyl)propanoate Chemical compound COC1=CC(C(N)CC(=O)OC)=CC=C1OC1CCCC1 MQUATXVULWXAAN-UHFFFAOYSA-N 0.000 description 1
- HCFXLWSPGIJRSL-UHFFFAOYSA-N methyl 3-amino-3-(4-ethoxy-3-methoxyphenyl)propanoate Chemical compound CCOC1=CC=C(C(N)CC(=O)OC)C=C1OC HCFXLWSPGIJRSL-UHFFFAOYSA-N 0.000 description 1
- OSPSZSHONUEXMS-UHFFFAOYSA-N methyl 3-amino-3-(4-methoxy-3-phenylmethoxyphenyl)propanoate Chemical compound COC(=O)CC(N)C1=CC=C(OC)C(OCC=2C=CC=CC=2)=C1 OSPSZSHONUEXMS-UHFFFAOYSA-N 0.000 description 1
- XKIOBYHZFPTKCZ-UHFFFAOYSA-N methyl 3-amino-3-phenylpropanoate Chemical compound COC(=O)CC(N)C1=CC=CC=C1 XKIOBYHZFPTKCZ-UHFFFAOYSA-N 0.000 description 1
- UZCXPYDBYUEZCV-UHFFFAOYSA-N methyl 3-aminopropanoate Chemical compound COC(=O)CCN UZCXPYDBYUEZCV-UHFFFAOYSA-N 0.000 description 1
- KVQGGLZHHFGHPU-UHFFFAOYSA-N methyl 4-aminobutanoate Chemical compound COC(=O)CCCN KVQGGLZHHFGHPU-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- 150000003151 propanoic acid esters Chemical class 0.000 description 1
- SGUKUZOVHSFKPH-YNNPMVKQSA-N prostaglandin G2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](OO)CCCCC)[C@H]2C\C=C/CCCC(O)=O SGUKUZOVHSFKPH-YNNPMVKQSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KWKGVOHXCVOYRS-UHFFFAOYSA-N tert-butyl 4-(hydroxymethyl)thiophene-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CSC=C1CO KWKGVOHXCVOYRS-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to pyrroline-2-one derivatives having an activity of inhibiting the release of tumor necrosis factor (TNF) from cells, a process for their preparation and their use as pharmaceutical active ingredients.
- TNF tumor necrosis factor
- Tumor necrosis factor is a major cytokine released by mononuclear phagocytes in response to immune stimulation.
- Administration of TNFa to animals and humans can cause inflammation, fever, cardiovascular dysfunction, hemorrhage, coagulation, and a series of acute reactions similar to acute infections and shock states.
- Excessive or uncontrolled TOF x in animals or in humans often indicates the following diseases:
- TNFo also plays an important role in bone resorption disorders including arthritis [Betolinni et al., Nature 319, 516-8 (1986)] Both in vitro and in vivo tests demonstrate that TNFa can stimulate osteoclasts (Osteoclast) The generation and activation of the bone resorbs and inhibits bone formation.
- TNFa Tissue Int. 46 (Suppl.), S3-10 (1990)] in bone marrow transplantation.
- US Calci. Tissue Int. 46 (Suppl.), S3-10 (1990)
- the immune response is closely related to the increase in serum TNFo levels in patients [Holler et al., Blood, 75(4), 1011-1016 (1990)].
- TNFoc Fatal hyperacute neurological syndrome Brain-type malaria is also associated with high levels of TNFoc in the blood, which is the most dangerous form of malaria.
- serum TNFo levels are directly related to the condition and can often occur in patients with acute malaria attacks [Grau et al., N. Engl. J. Med. 320 (24), 1586-91 (1989)
- TOFot also plays an important role in chronic pneumonia. Storage of silicon-containing particles in the lungs can cause silicosis. Silicosis is progressive respiratory failure caused by fibrosis of lung tissue. In animal pathology models, antibodies to TNFoc completely block the mouse lung fibrosis induced by silica dust [Pignet et al., Nature, 344:245-7 (1990)]. Animal experiments have also demonstrated that TNFoc is abnormally high in animal serum of pulmonary fibrosis caused by silica dust or asbestos ash [Bissonnette et al., Inflammation 13 (3), 329-339 (1989)].
- TNFa levels in lung tissue of patients with pulmonary nodules are also much higher than in normal people [Baughman et al, J. Lab. Clin. Med. 115(l), 36-42 (1990)] o suggesting TNFo inhibition
- the agent is of great significance in the treatment of chronic lung disease and lung injury.
- TNFa The cause of inflammation in Reperfosion Injury may also be due to abnormal levels of TNFa in the patient, and TNFa is considered to be the chief culprit in tissue damage caused by ischemia [Uadder et al., PNAS 87, 2643- 6 (1990)]
- TNFa can initiate replication of retroviruses including HIV-1 [Duh et al., Proc. Nat. Acad. Sci., 86, 5974-5 (1989)].
- T-cells need to be activated before HIV enters T-cells, and once activated sputum-cells are infected with HIV virus, these sputum-cells must remain active in order to allow the HIV virus gene to be successfully expressed and/or to replicate HIV virus successfully.
- Cytokines, especially TNFoc play an important role in T-cell-regulated HIV protein expression or in viral replication. Therefore, inhibition of TOFc production may inhibit the replication of HIV virus in T-cells.
- cAMP regulates many cell-like functions, such as inflammatory responses, including asthma and inflammation [Lome and Cheng, Drugs of the futune, 17(9), 799-807, 1992].
- An increase in the cAMP concentration of leukocytes during inflammation inhibits leukocyte activation, followed by the release of inflammatory regulators, including TNFoc, which exacerbate inflammation in the patient. Therefore, inhibition of the release of TNFcc can alleviate inflammatory diseases including asthma.
- TNFoc promotes the expression of cell adhesion molecules by promoting the synthesis and release of inflammatory cytokines [Abboud HE Kidney Int. 1993; 43:252-267] [Egido J. et al, Kidney Int. 1993; 43 (suppl 39) :59-64], and the synthesis and release of prostaglandin G 2 (PGE 2 ) and platelet activating factor (PAF) [Cammusi G. et al, Kidney Int., 43 (suppl 39): 32-36], The inflammatory cells are aggregated and adhered, microvascular expansion and permeability are enhanced, fever is induced, neutrophils are increased, and hemodynamic changes are caused by inflammatory reactions, thereby causing damage to renal cells. Many studies suggest that TNFa plays an important role in the pathogenesis and deterioration of nephritis.
- TNFoc participates in the regulation of immune function by activating macrophages, immunostimulating T lymphocyte proliferation, regulating B lymphocyte differentiation and enhancing the cytotoxicity of natural killer cells (NK).
- NK natural killer cells
- TNFa levels in patients and/or increasing their cAMP levels is an effective strategy for the treatment of many inflammatory, infectious, immunological or malignant diseases, including but not limited to Sepsis Shock, endotoxin Shock, Hemodynamic Shock, Sepsis Syndrom, Post Ischemic Reperfusion Injury, Malaria, Mycobacterial Infection, Meningitis Meningitis), Psoriasis, Congestive Heart Failure, Fibrotic disease, cachexia, transplant rejection, cancer, autoimmu e disease, AIDS Opportunistic Infection in AIDS, Rheumatoid Arthritis (RA), Hepatitis, Nephritis, Rheumatoid Spondylitis, etc.
- Sepsis Shock endotoxin Shock
- Hemodynamic Shock Sepsis Syndrom
- Post Ischemic Reperfusion Injury Malaria, Mycobacterial Infection, Meningitis Meningitis
- Psoriasis Congestive Heart Failure
- TNFo antibodies have made breakthroughs in the clinical treatment of arthritis, and TNFoc antibodies have become an indispensable drug in arthritis treatment programs.
- antibody drugs have disadvantages such as high drug price, difficulty in production, and immunotoxicity. Therefore, the development of low-toxicity and high-efficiency small molecule TNFc inhibitors has great social and economic value.
- the present invention relates to pyrroline-2-one derivatives of the formula (I) or (II) and various inorganic or organic acid salts thereof, processes for their preparation and their use as inhibitors of TNFa release from cells Application of active ingredients:
- a and B respectively represent C3 ⁇ 4, CO, SO, S0 2!
- D represents a S, NH, Nd. 5 hydrocarbon group
- R 1 means H, 1-2 are the same or different? , Cl, Br, C M hydrocarbyl, OH, OC 14 hydrocarbyl, N0 2 , NHC(0)Ci -4 hydrocarbyl, N3 ⁇ 4, NH(C M hydrocarbyl), N(. 4 hydrocarbyl) 2;
- R 2 represents a F, CF 3 , H, C M hydrocarbon group
- R 4 represents H, ( 1-8 hydrocarbyl, (CH 2 ) n Ar-R 5 ;
- Ar represents a 4-8 member hydrocarbon ring or aromatic ring having 0-4 heteroatoms
- E represents a hydrocarbon ring or an aromatic ring having 4 to 4 hetero atoms
- W represents 0, S, NH, CH 2 ;
- n 0, 1, 2, 3, 4, 5 or 6;
- n 0, 1, 2, 3, 4;
- Ar and E when Ar and E represent an aromatic ring, it may be a phenyl group, a naphthalene ring, a pyridyl group, an imidyl group, a thiophene, a furan, an anthracene, an isoindole, a benzothiophene, a benzofuran or a formula (111).
- Ar and E represent a hydrocarbon ring
- it may be a cyclopentane ring, a cyclohexane ring or a heterocyclic ring of the formula (VI), wherein G represents 0, S, -NR 6 and Y represents 1,2-ethylene group, 1 a hetero atom-containing terminal subunit such as 3-propylene, 1,4-butylene, 1,5-pentylene, 1,6-hexylene and C3 ⁇ 4OCH 2 , C 3 ⁇ 4SCH 2 or CH 2 NR 7 CH 2 , wherein R 6 and R 7 represent a H, C 1-4 hydrocarbon group, respectively.
- the C w hydrocarbon group of the present invention may be a linear or branched hydrocarbon group, and may be F, CN, OH, COOH, C(0)NH 2 , NHC(0)R 8 , NR 8 R 9 , NHC ( 0) N3 ⁇ 4, NHC(NH)NH 2 > OR 8 , SR 9 , wherein R 8 and R 9 each represent a C 1-4 hydrocarbon group.
- the C M hydrocarbyl group, the d 6 hydrocarbyl group, the CM hydrocarbyl group of the present invention may be a linear or branched hydrocarbon group, and may be F, CN, OH, COOH, C(0)N3 ⁇ 4, NHC(0)R 8 , NR 8 R 9 , NHC(0)NH 2 , NHC(NH)NH 2 > OR 8 , SR 9 , wherein R 8 and R 9 each represent a C M hydrocarbon group.
- the present invention inhibits the release of cytokine TOFa from PBMCs in human peripheral blood after inhibiting lipopolysaccharide (LPS) stimulation of a compound of formula (I) or formula (II).
- LPS lipopolysaccharide
- Compounds of the formula (I) or formula ( ⁇ ) suitable for use as a medicament are those wherein m represents a natural number of 1-4, particularly those wherein m represents 1, 2, 3.
- the compound of the formula (I) or the formula (II) suitable for use as a medicament is those wherein 1, n represents a natural number of 0-3, respectively, particularly those wherein 1, n represents 0, 1, and 2, respectively.
- a compound of formula (I) or formula (II) suitable for use as a medicament is that R 1 represents H, 1-2 identical or different F, Cl, Br, CH 3 , C 3 ⁇ 4CH 3 , OH, OCH 3 , OCH 2 CH 3, N3 ⁇ 4, NHCH 3 , NHCH 2 CH 3, N (CH 3) 2 are those compounds, in particular those compounds wherein R 1 represents H, F, NH 2's.
- Compounds of formula (I) or formula (II) suitable for use as a medicament are those wherein R 2 represents H, F, CH 3 .
- the compound of formula (I) or formula (II) suitable for use as a medicament is Ar, and £ represents phenyl, naphthalene ring, pyridyl, imidazyl, thiophene, furan, hydrazine, isoindole, benzo, respectively. Those compounds of thiophene, benzofuran.
- Compounds of formula (I) or formula (II) suitable for use as a medicament are those wherein R 5 represents H, 1-4 are the same or different, Cl, methyl, ethyl, trifluoromethyl, OH, CH 3 COO, OOCCH 2 CH 3 , OOCCH 2 CH 2 CH 3 , OCH 3 , ethoxy, isopropoxy, propoxy, butoxy, cyclopentyloxy, benzyloxy, phenoxy, pyridine group, a phenoxy group, substituted benzyloxy, substituted phenoxy, substituted pyridyl-methoxy, substituted phenoxyethyl, NHC (0) Me, NHC (0) Et, NH 2, methylamino, Ethylamino, dimethylamino, CN, COOC3 ⁇ 4, COOCH 2 CH 3 , COOCH 2 CH 2 CH 3 , COOCH(C ) 2 , C(0)NH 2 , C(0)NHCH 3 , C(0)
- the compound represented by the formula (I) or the formula ( ⁇ ) according to the present invention may be an R body, a S body or a racemate when used as a pharmaceutically active ingredient; it may be an E body, a Z body, or an E/Z body mixture; It may be a prodrug of a compound of formula (I) or formula (II); it may be a metabolite of a compound of formula (I) or formula ( ⁇ ).
- the compound of the formula (I) or the formula ( ⁇ ) according to the present invention when used as a pharmaceutically active ingredient, it may be in the form of a free base or a mineral acid salt, including a hydrochloride, a sulfate, a nitrate, a phosphate, or Is an organic acid salt form, which includes sulfonate, acetate, formate, fumarate, maleate, citrate, tartrate, malate, benzoate, ascorbate, glucose Acid salt, lactate, succinate, trifluoroacetate.
- a mineral acid salt including a hydrochloride, a sulfate, a nitrate, a phosphate, or Is an organic acid salt form, which includes sulfonate, acetate, formate, fumarate, maleate, citrate, tartrate, malate, benzoate, ascorbate, glucose Acid salt, lactate, succinate, trifluoroacetate.
- the invention also relates to a process for the preparation of a compound of formula (I) or formula (II),
- a and B represent CH 2 , CO, SO, S0 2 respectively!
- D represents a S, NH, Nd. 6 hydrocarbon group
- R 1 means H, 1-2 are the same or different? , Cl, Br, C 14 hydrocarbyl, OH, OC M hydrocarbyl, N0 2 , NHC(0)d.4
- CH CHN0 2
- C ( NH ) NH (C 1-4 hydrocarbon)
- C (C 1-4 hydrocarbyl) NCN
- C (C 1-4 hydrocarbyl) NC (0) C 1-4 hydrocarbyl
- C ( C 1-4 hydrocarbyl) C(CN) 2
- C (C M hydrocarbyl) CHN0 2 .
- R 4 represents H, CL 8 hydrocarbyl, (CH 2 ) n Ar-R 5 ;
- Ar represents a 4-8 member hydrocarbon ring or aromatic ring having 0-4 heteroatoms
- R 5 represents H, 1-4 identical or different F, Cl, CF 3 , CN, C M hydrocarbyl, OH, OC M hydrocarbyl, HC(0)C 1-4 hydrocarbyl, NH 2 , NH (C 1- C4 alkyl), N (C 1-4 hydrocarbyl) 2, C (0) OC 1-4 hydrocarbon group, OOCC M hydrocarbyl, C (0) NH 2, C (0) NH (C M hydrocarbyl), CN d hydrocarbyl) 2, c cw hydrocarbon group, SC Cw hydrocarbon group, S0 2 C 1-4 hydrocarbon group, 0 2 CC 1-4 hydrocarbon group, E, W-(CH 2 )iE ; E represents a hydrocarbon ring or aromatic ring of 4-8 members having 0-4 heteroatoms;
- W means 0, S, NH, CH 2 !
- n 0, 1, 2, 3, 4, 5 or 6;
- n 0, 1, 2, 3, 4;
- D, R 1 , R 2 , R 3 , R 4 , m are the same as those in the formulae (1) and ( ⁇ ), ⁇ represents Cl, Br, I, Ms, Ts, and Q represents a methyl group.
- a tert-butyl group which gives a compound represented by the formula (X) or the formula (XI), wherein the group represented by D, R ⁇ R 2 , R 3 and R m is the same as in the formulae (1) and (II), Q Denotes methyl, tert-butyl;
- the charge ratio of the compound represented by the formula (VII) or (VIII) to the compound of the formula (IX) may be any molar ratio from 3:1 glj l :3.
- the reaction may be carried out with an inorganic base including, but not limited to, NaH, KH, Ca3 ⁇ 4, K 2 C0 3 , Na 2 C0 3 > HC0 3 , NaHCOss Li 2 C0 3 , Cs 2 C0 3 , LiOH, KOH, NaOH, Ca(OH) 2 , K 3 P0 4 , K 2 HP0 4 or an organic base, the amount of the base being between 50% and 300% by mole.
- an inorganic base including, but not limited to, NaH, KH, Ca3 ⁇ 4, K 2 C0 3 , Na 2 C0 3 > HC0 3 , NaHCOss Li 2 C0 3 , Cs 2 C0 3 , LiOH, KOH, NaOH, Ca(OH) 2 , K 3 P0 4 , K 2 HP
- the reaction can be carried out in an organic solvent such as dichloromethane, chloroform, acetone, butanone, hydrazine, hydrazine-dimethylformamide, dimethyl sulfoxide, ethylene glycol dimethyl ether, tetrahydrofuran, pyridine, acetonitrile. It can be carried out under heterogeneous conditions, especially in the presence of a phase transfer catalyst.
- organic solvent such as dichloromethane, chloroform, acetone, butanone, hydrazine, hydrazine-dimethylformamide, dimethyl sulfoxide, ethylene glycol dimethyl ether, tetrahydrofuran, pyridine, acetonitrile.
- a compound represented by the formula (XII) or the formula (XIII) is dehydrated and cleaved to obtain a corresponding compound represented by the formula (I) or the formula (II).
- the reaction can be carried out in an organic solvent such as dichloromethane, chloroform, acetone, butanone, hydrazine, hydrazine-dimethylformamide, dimethyl sulfoxide, ethylene glycol dimethyl ether, tetrahydrofuran, pyridine or acetonitrile.
- a condensing agent such as thionyl chloride, DCC, CDI or EDCL may be added as a catalyst by adding a pyridine compound such as DMAP or 4-(1-pyrroline)pyridine.
- the invention further relates to a second process for the preparation of a compound of formula (I) or formula (II), characterized by formula 0 IV) or (XV),
- the charge ratio at the time of reacting the compound represented by the formula (XIV) or the formula (XV) with the compound of the formula (IX) may be any molar ratio from 3:1 to 1:3.
- the reaction may be a base, including but not limited to NaH, KH, CaH 2 , K 2 C0 3 , Na 2 C0 3 , KHC0 3 , NaHC0 3 , Li 2 C0 3 , Cs 2 C0 3 , LiOH, KOH, NaOH, Ca(OH 2 , K 3 P0 4 , K 2 HP0 4 , trimethylamine, triethylamine, diethylisopropylamine, 4-methylmorphine, 1-methylcyclohexylamine, 1-methylpyrroline, pyridine,
- the amount of base is between 50% and 300% by mole.
- the reaction can be carried out in an organic solvent such as dichloromethane, chloroform, acetone, methyl ethyl ketone, hydrazine, hydrazine-dimethylformamide, dimethyl sulfoxide, ethylene glycol dimethyl ether, tetrahydrofuran, pyridine or acetonitrile. It is carried out under heterogeneous conditions, especially in the presence of a phase transfer catalyst.
- organic solvent such as dichloromethane, chloroform, acetone, methyl ethyl ketone, hydrazine, hydrazine-dimethylformamide, dimethyl sulfoxide, ethylene glycol dimethyl ether, tetrahydrofuran, pyridine or acetonitrile.
- the dehydration and ring closure reaction of the intermediate can be carried out in an organic solvent such as dichloromethane, chloroform, acetone, butanone, hydrazine, hydrazine-dimethylformamide, dimethyl sulfoxide, ethylene glycol dimethyl ether, tetrahydrofuran, pyridine, acetonitrile.
- an organic solvent such as dichloromethane, chloroform, acetone, butanone, hydrazine, hydrazine-dimethylformamide, dimethyl sulfoxide, ethylene glycol dimethyl ether, tetrahydrofuran, pyridine, acetonitrile.
- a condensing agent such as thionyl chloride, DCC, CDI or EDCI may be added to the reaction, and a pyridine compound such as DMAP or 4-(1-pyrroline)pyridine may also be added as a catalyst.
- the present invention relates to the use of a compound of formula O or formula (II) as a pharmaceutical active ingredient
- a and B respectively represent C3 ⁇ 4, CO, SO, S0 2;
- D represents a hydrocarbon group of S, NH, NCw;
- R 1 means H, 1-2 are the same or different? , Cl, Br, C 1-4 hydrocarbyl, OH, OC 1-4 hydrocarbyl, N0 2 , NHC(0)C 1-4 hydrocarbyl, NH 2 , NH Cw hydrocarbyl), N (C M hydrocarbyl) 2;
- R 2 represents a F, CF 3 , H, C M hydrocarbon group
- R 3 represents F, Cl, H, CL 4 hydrocarbon group, OH, CHCOI ⁇ hydrocarbon group, O ⁇ jg group, NHC(0)C M hydrocarbon group, NH 2 , : ⁇ ! ! ⁇ ! ⁇ hydrocarbyl), N(C 1-4 hydrocarbyl) 2, C(0)OC M hydrocarbyl, C(0)N3 ⁇ 4, CiC NH Cw hydrocarbyl), C(0)N(d hydrocarbyl) 2, C(0)NHOH , C(0)NH(OC 1-4 hydrocarbyl), C(0)C 1-4 hydrocarbyl, S(0)C 1-4 hydrocarbyl, SC ⁇ CM hydrocarbyl, S0 2 NHC 1-4 hydrocarbyl, NHS0 2 C M hydrocarbon group, 0 2 CCi.
- R 4 represents H, CM hydrocarbyl, (C3 ⁇ 4) n Ar-R 5 ;
- Ar represents a 4-8 member hydrocarbon ring or aromatic ring having 0-4 heteroatoms
- R 5 represents H, 1-4 identical or different F, Cl, CF 3 , CN, C M hydrocarbyl, OH, OC M hydrocarbyl, NHC(0)C 1-4 hydrocarbyl, NH 2 , NH (Ci -4) Hydrocarbyl), N(C 1-4 hydrocarbyl) 2 , C(0)OCi -4 hydrocarbyl, OOCC 1-4 hydrocarbyl, C(0)NH 2 , Hydrocarbyl), C(O)N(C 1-4 hydrocarbyl) 2, CC CM hydrocarbyl, s(o)c 1-4 hydrocarbyl, so 2 c 1-4 hydrocarbyl, o 2 cc 1-4 hydrocarbyl, E, W -(CH 2 )iE;
- E represents a hydrocarbon ring or an aromatic ring having 4 to 4 hetero atoms
- W means 0, S, NH, CH 2! 1 means 0, 1, 2, 3, 4;
- n 0, 1, 2, 3, 4, 5 or 6;
- n 0, 1, 2, 3, 4;
- the indications that can be used for treatment when the compound of formula (I) or formula (II) is used as a pharmaceutically active ingredient are all those diseases and physiology which can be effectively alleviated and treated by reducing the level (concentration) of TNFct in a patient.
- Abnormalities including but not limited to inflammatory diseases, infectious diseases, immune diseases or malignant diseases.
- Specific disease types include, but are not limited to, Sepsis Shock, Endotoxin Shock, Hemodynamic Shock, Sepsis Syndrom, Post Ischemic Reperfusion Injury, Malaria ( Malaria), Mycobacterial Infection Meningitis; Psoriasis.
- the present invention relates to a formulation containing at least one compound of formula (I) or formula (II):
- a and B respectively represent CH 2 , CO, SO, S0 2 ;
- D represents S, NH, NQ. 6 hydrocarbon group
- R 1 means H, 1-2 are the same or different? , Cl, Br, C 1-4 hydrocarbyl, OH, OCw hydrocarbyl, N0 2 , NHC(0)Cj. 4 hydrocarbyl, NH 2 , NH(Ci -4 hydrocarbyl), N(C "hydrocarbyl" 2;
- R 2 represents a F, CF 3 , H, C M hydrocarbon group
- R 4 represents H, 8 hydrocarbyl, (CH 2 ) n Ar-R 5 ;
- Ar represents a 4-8 member hydrocarbon ring or aromatic ring having 0-4 heteroatoms
- R 5 represents H, 1-4 identical or different F, Cl, CF 3 , CN, C M hydrocarbyl, OH, OQ.4 hydrocarbyl, NHC(0)C 1-4 hydrocarbyl, NH 2 , NH (C 1 -4 hydrocarbyl), N(C 1-4 hydrocarbyl) 2 , C(0)OC 1-4 hydrocarbyl, OOC .4 hydrocarbyl, C(0)NH 2 , C(0)NH(C M 3 ⁇ 4), C (0) N (C M hydrocarbyl) 2, C(0)C 1-4 hydrocarbyl, SCC ⁇ Cw hydrocarbyl, SC ⁇ Cw hydrocarbyl, 0 2 CC M hydrocarbyl, E, W-(C3 ⁇ 4), E;
- W represents 0, S, NH, CH 2 ;
- n 0, 1, 2, 3, 4;
- the preparation may contain, in addition to at least one compound represented by the formula (I) or ( ⁇ ), a carrier adjuvant, a filler, a solvent, a diluent, a colorant, and a binder.
- a carrier adjuvant for a pharmaceutical preparation through gastrointestinal tract, intravenous injection, intraperitoneal administration, intradermal injection, intramuscular injection, nasal administration, intraocular administration, inhalation administration, intragastric administration.
- Specific disease types include, but are not limited to, Sepsis Shock, Endotoxin Shock, Hemodynamic Shock, Sepsis Syndrom > Post Ischemic Reperfsion Injury > Malaria, Mycobacterial Infection, Meningitis, Psoriasis, Congestive Heart Failure, Fibrotic disease, Cachexia, Transplantation of immune rejection, cancer, autoimmune disease, Opportunistic Infection in AIDS, leprosy nodular erythema, lupus erythematosus, refractory lupus erythematosus, Behcet syndrome, limitations Ileitis, myelodysplastic syndrome, rheumatoid arthritis (RA;), hepatitis, nephritis, rheumatoid spondylitis, multiple myeloma, thyroid tumor, kidney cancer, prostate cancer, lymphoma, Leukemia, liver cancer, glioma, colon cancer, lung cancer, stomach cancer, breast
- the compound of the formula (I) or the formula (II) according to the present invention when used as a medicament, it can be used in combination with other suitable pharmaceutically active ingredients.
- PBMC LPS-stimulated monocytes
- LPS lipopolysaccharide
- PBMCs are obtained from heparin-treated blood from at least three volunteer donors.
- PBMCs were obtained from the heparin-treated blood of at least three volunteer donors by a known method, and the PBMCs were collected and used in 1640 medium (10% calf serum, 2 mM L-glutamylamine, 100 mM mercaptoethanol). , 50 wg/ml streptomycin, 50 U/ml penicillin) was washed three times.
- the PBMCs were added to a 24-well plate and formulated to a concentration of 1 X 10 6 cells/ml using 1640 medium.
- test compound is dissolved in dimethyl sulfoxide, and a test substance solution prepared to a desired concentration is added to the above cell culture solution, and incubated in a CO 2 incubator (5% C0 2 , 90% humidity) for 1 hour. , then add LPS (Sigma) to 0.1 ⁇ g/ml (except controls).
- CDI ⁇ , ⁇ -carbonyldiimidazole
- DCM dichloromethane
- THF tetrahydrofuran
- TFA trifluoroacetic acid
- DMAP 4-(N,N-dimethylamino)pyridine
- TEA triethylamine
- DMSO dimethyl sulfoxide
- BOC 2 0 di-tert-butyl dicarbonate
- BTOH 1-hydroxybenzotriazole
- DCC ⁇ , ⁇ -dicyclohexyl Carbodiimide.
- Methyl 3-amino-3-(3-propoxy-4-methoxyphenyl)propanoate (8) Step of repeating synthesis of a compound by using 3-amino-3-(3-propoxy-4-methoxyphenyl)propionic acid instead of 3-amino-3-(3,4-dimethoxyphenyl)propionic acid An oily product is obtained.
- the solid was dissolved in 3 ml of anhydrous methanol and 3 tnl of THF, 12 ml of aqueous methylamine solution (25%-30%) was added, stirred at room temperature overnight, steamed with methanol and THF, 20 ml of CHCl 3 and 20 ml of 2N hydrochloric acid were added to separate the hydrochloric acid layer.
- Example 1 The experimental procedure of Example 1 was repeated using Compound 7 in place of Compound 6. A solid product was obtained.
- Example 1 The experimental procedure of Example 1 was repeated using Compound 8 in place of Compound 6. A solid product was obtained.
- Example 4 3-(3-Isopropoxy-4-methoxyphenyl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H)- Methyl propionate
- the compound procedure of Example 1 was repeated using Compound 9 instead of Compound 6.
- the solid product was obtained.
- Example 5 3-(3-Cyclopentyloxy-4-methoxyphenyl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H:) -Base) Methyl propionate
- the procedure of Example 1 was repeated using Compound 10 instead of Compound 6.
- the solid product was obtained.
- Example 6 3-(3-Benzyloxy-4-methoxyphenyl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6 ⁇ )- Methyl propionate was repeated with compound 11 in place of compound 6. The experimental procedure of Example 1 was repeated to give a solid product.
- Example 1 The experimental procedure of Example 1 was repeated using Compound 12 instead of Compound 6 to give a solid product.
- Example 1 The experimental procedure of Example 1 was repeated using a compound instead of a compound to obtain a solid product.
- Example 9 3-(3-Methoxy-4-isopropoxyphenyl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H)- Methyl propionate was replaced with a compound in place of the compound. The experimental procedure of Example 1 was repeated to give a solid product.
- Example 10 3-(3-methoxy-4-cyclopentyloxyphenyl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H)- Methyl propionate was replaced with a compound in place of the compound.
- the experimental procedure of Example 1 was repeated to give a solid product.
- Example 11 3-(3-methoxy-4-benzyloxyphenyl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H)- Methyl propionate was replaced with compound 16 in place of the compound.
- the experimental procedure of Example 1 was repeated to give a solid product.
- Example 1 The experimental procedure of Example 1 was repeated using a compound instead of a compound to obtain a solid product.
- Example 1 Substituting the compound for the compound The experimental procedure of Example 1 was repeated to obtain a solid product.
- Example 1 The experimental procedure of Example 1 was repeated using a compound instead of a compound to obtain a solid product.
- Example 1 The experimental procedure of Example 1 was repeated using a compound instead of a compound to obtain a solid product.
- Example 1 The experimental procedure of Example 1 was repeated using a compound instead of a compound to obtain a solid product.
- Example 19 L-2-(4,6-Dioxy-4H-thiophene[3,4-c]pyrrole-5(6H)-yl)-3-phenylpropanoic acid methyl ester
- Example 20 3-(3-methylthiophen-2-yl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H)-yl)propanoic acid ester
- Example 1 The experimental procedure of Example 1 was repeated using Compound 25 instead of Compound 6. A solid product was obtained. MS (m/z) x 336 [M+l]+. Example 21, 3-(3-Ethoxy-4-methoxyphenyl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H)-yl Ethyl propionate was replaced with compound 26 in place of compound 6. The experimental procedure of Example 1 was repeated to give a solid product. iH NMR (CDC1 3 ): ⁇ 7.78 (s,
- Example 22 3-(3-methoxy-4-ethoxyphenyl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H)-yl
- the ethyl propionate was replaced with the compound 27 in place of the compound 6.
- the experimental procedure of Example 1 was repeated to obtain a solid product.
- Example 23 3-(3,4-Dimethoxyphenyl)-3-(l-amino-4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H)- Methyl propionate
- 0.239 g of compound 6 0.199 g of compound 5 and 10 ml of dry THF were added and stirred at room temperature overnight.
- the solid was dissolved in 10 ml of acetone, 0.781 g of insurance powder Na 2 S 2 0 4 and 10 ml of water were added, and the reaction was refluxed for 10 minutes. After cooling, 20 ml of water was added, and the mixture was extracted three times with 20 ml of ethyl acetate, and then combined with water. and washed with saturated saline solution, it was dry over anhydrous MgS0 4, filtered and the solvent evaporated to dryness to give 0.079 g of yellow solid after purification by column chromatography.
- Example 23 The experimental procedure of Example 23 was repeated using Compound 10 in place of Compound 6. A solid product was obtained.
- Example 23 The experimental procedure of Example 23 was repeated using Compound 12 instead of Compound 6. A solid product was obtained.
- Example 23 The experimental procedure of Example 23 was repeated using Compound 13 instead of Compound 6. A solid product was obtained.
- Example 23 The experimental procedure of Example 23 was repeated using Compound 16 in place of Compound 6. A solid product was obtained.
- Example 23 The experimental procedure of Example 23 was repeated using Compound 22 instead of Compound 6. A solid product was obtained. 3 ⁇ 4 NMR (CDC1 3 -CD 3 0D).- ⁇ 7.34-7.50 (m, 5H), 6.92 (s, 1H), 5.87 (s, 1H), 3.80 (s, 3H).
- Example 23 The experimental procedure of Example 23 was repeated using Compound 23 instead of Compound 6. A solid product was obtained.
- 1H NMR (CDCl 3 -CD 3 OD) : ⁇ 7.33-7.50 (m, 5H), 6.93 (s, IH), 5.86 (s, 1H), 3.80 (s, 3H).
- Example 33 The experimental procedure of Example 33 was repeated using Compound 29 instead of Compound 28 to give a solid product.
- Example 33 The experimental procedure of Example 33 was repeated using Compound 30 instead of Compound 28 to give a solid product.
- 3 ⁇ 4 NMR (CDC1 3 ) : ⁇ 7.84 (s,
- Example 36 3-(3-Ethoxy-4-methoxyphenyl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H)-yl Propiononitrile
- the experimental procedure of Example 33 was repeated using Compound 31 instead of Compound 28 to give a solid product.
- Example 33 The experimental procedure of Example 33 was repeated using Compound 32 instead of Compound 28 to give a solid product.
- Example 38 3-(3-methoxy-4-ethoxyphenyl)-3-(l-amino-4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5 ( 6H)-yl)propanenitrile
- 0.264 g of Compound 28 0.264 g
- 0.239 g of Compound 5 and 10 ml of dry THF were added and stirred at room temperature overnight.
- the CDI was added 0.3126 g, refluxed for 3 hours, the solvent was evaporated, 50ml of ethyl acetate was added, washed successively with saturated aqueous NaHC0 3, water, 1N hydrochloric acid, water and a saturated saline solution, dried over anhydrous M g S0 4, filtered, evaporated to dryness
- the solvent gave 0.415 g of solid 3-(3-methoxy-4-ethoxyphenyl)-3-(1-nitro-4,6-dioxo-4H-thiophene[3,4-c]pyrrole- 5(6H)-yl)propionitrile.
- the solid was dissolved in 10 ml of acetone, 0.901 g of insurance powder Na 2 S 2 0 4 and 10 ml of water were added, and the reaction was refluxed for 10 minutes. After cooling, 20 ml of water was added, and the mixture was extracted three times with 30 ml of ethyl acetate, and then combined with water. and a saturated saline solution, dried over anhydrous M g S0 4, filtered, and the solvent was evaporated, after purification by column chromatography to give 0.129 g of yellow solid.
- Example 38 The experimental procedure of Example 38 was repeated using Compound 29 instead of Compound 28.
- Example 38 The experimental procedure of Example 38 was repeated using Compound 30 instead of Compound 28.
- Example 41 3-(3-Ethoxy-4-methoxyphenyl)-3-(l-amino-4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5 ( The procedure of Example 38 was repeated using Compound 31 instead of Compound 28 to give a solid product.
- Example 38 The experimental procedure of Example 38 was repeated using Compound 32 instead of Compound 28 to give a solid product.
- Example 43 3-(3-methoxy-4-benzyloxyphenyl)-3-(4,6-dioxo-4H-thiophene[3,4-c]pyrrole-5(6H)- Propionamide
- 0.12 g of compound 33, 0.062 g of compound 3 and 10 ml of dry DMF were added and stirred at room temperature overnight.
- reaction was carried out for 6 hours, and the reaction solution was poured into 100 ml of water, and extracted with 50 ml of CHCl 3 , and the organic layer was washed successively with saturated NaHC (3 ⁇ 4 aqueous solution, water, 1N hydrochloric acid, water and saturated aqueous salt solution, dried anhydrous MgSO 4 , filtered, Evaporate the solvent and purify it by column chromatography to give 0.122 g White solid.
- Example 43 The experimental procedure of Example 43 was repeated using Compound 34 instead of Compound 33 to give a solid product.
- Example 43 The experimental procedure of Example 43 was repeated using Compound 35 instead of Compound 33 to give a solid product.
- Example 47 The experimental procedure of Example 43 was repeated using Compound 36 instead of Compound 33 to give a solid product. MS (m/z) : 511 [M-1] + .
- Example 47
- Example 43 The experimental procedure of Example 43 was repeated using Compound 37 instead of Compound 33 to give a solid product.
- Example 50 The experimental procedure of Example 48 was repeated using Compound 39 instead of Compound 38 to give a solid product. MS (m/z): 362 [M+l] + .
- Example 50
- Example 50 The experimental procedure of Example 50 was repeated using Compound 44 instead of Compound 41 to give a solid product.
- Example 54 5-(l-(3-Methoxy-4-benzyloxyphenyl)-3-dimethylaminopropyl)-5H-thiophene[3,4-c]pyrrole-4, 6-Diketone
- 0.076 g of compound 47, 0.038 g of compound 3 and 10 ml of dry THF were added and stirred at room temperature overnight.
- Example 55 5-(l-(3-methoxy-4-benzyloxyphenyl)-3-diethylaminopropyl)-5H-thiophene[3,4-c]pyrrole-4, The 6-diketone was replaced with compound 48 in place of compound 47. The experimental procedure of Example 54 was repeated to give a solid product. MS (m/z): 479 [M+l]+.
- Example 56 5-(1-(3-methoxy-4-benzyloxyphenyl)-3-(piperidin-1-yl)propyl)-5H-thiophene [3,4-c] The pyrrole-4,6-dione was replaced with compound 49 in place of compound 47. The experimental procedure of Example 54 was repeated to give a solid product.
- Example 59 The experimental procedure of Example 59 was repeated with hydrazine hydrate instead of hydroxylamine hydrochloride to give a solid product. MS (m/z) : 779 [2 ⁇ +1]+.
- Example 62 The experimental procedure of Example 62 was repeated using Compound 12 instead of Compound 7. A solid product was obtained.
- Example 64 3-(3-Ethoxy-4-methoxyphenyl)-3-(4-oxo-4H
- Example 62 The experimental procedure of Example 62 was repeated using Compound 31 instead of Compound 7. A solid product was obtained.
- Example 62 The experimental procedure of Example 62 was repeated using Compound 32 instead of Compound 7. A solid product was obtained.
- Example 66 3-(3-methoxy-4-ethoxyphenyl)-3-(4-oxo-4H-thiophene[3,4-c]pyrrole-5(6H)-yl)propanenitrile
- the experimental procedure of Example 62 was repeated using Compound 28 instead of Compound 7.
- a solid product was obtained.
- Example 68 The procedure of Example 23 was repeated using Compound 57 instead of Compound 6 to give a solid product: MS (m/z): 408 [M+l] + .
- Example 68 The procedure of Example 23 was repeated using Compound 57 instead of Compound 6 to give a solid product: MS (m/z): 408 [M+l] + .
- Example 68 Example 68,
- Example 70 The procedure of Example 23 was repeated using Compound 64 instead of compound to give a solid product: MS (m/z) - 376 [M+l] + .
- Example 70
- Example 23 The procedure of Example 23 was repeated using Compound 66 instead of Compound 6 to give a solid product: MS (m/z): 317 [M+l] + .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07816579.2A EP2083011B1 (en) | 2006-11-15 | 2007-10-16 | Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
JP2009536582A JP5491863B2 (ja) | 2006-11-15 | 2007-10-16 | 細胞の腫瘍壊死因子釈放を抑制できるピロリン誘導物及びその調製と応用 |
RU2009121676/04A RU2473551C2 (ru) | 2006-11-15 | 2007-10-16 | Лекарственное средство на основе дериватов пирролина для предотвращения омертвения клетки, пораженной опухолью, способ его производства и способ использования |
BRPI0716005-4A2A BRPI0716005A2 (pt) | 2006-11-15 | 2007-10-16 | Derivados de pirrolina contra a liberação celular do fator de necrose tumoral, seus métodos de preparação e seus usos |
AU2007321636A AU2007321636A1 (en) | 2006-11-15 | 2007-10-16 | Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
MX2009005222A MX2009005222A (es) | 2006-11-15 | 2007-10-16 | Derivados de pirrolina contra la liberacion del factor de necrosis tumoral en celulas; metodos de preparacion y su uso. |
US12/514,672 US8466191B2 (en) | 2006-11-15 | 2007-10-16 | Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
ES07816579.2T ES2498797T3 (es) | 2006-11-15 | 2007-10-16 | Derivados de pirrolina contra la liberación en las células del factor de necrosis tumoral, sus métodos de preparación y sus usos |
CA002669357A CA2669357A1 (en) | 2006-11-15 | 2007-10-16 | Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610129421A CN101186612B (zh) | 2006-11-15 | 2006-11-15 | 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用 |
CN200610129421.X | 2006-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008058448A1 true WO2008058448A1 (fr) | 2008-05-22 |
Family
ID=39401313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2007/002965 WO2008058448A1 (fr) | 2006-11-15 | 2007-10-16 | Dérivés de pyrroline agissant contre les cellules libérant le facteur de nécrose tumorale, procédés de préparation et utilisations associés |
Country Status (12)
Country | Link |
---|---|
US (1) | US8466191B2 (zh) |
EP (1) | EP2083011B1 (zh) |
JP (1) | JP5491863B2 (zh) |
KR (1) | KR20090086592A (zh) |
CN (1) | CN101186612B (zh) |
AU (1) | AU2007321636A1 (zh) |
BR (1) | BRPI0716005A2 (zh) |
CA (1) | CA2669357A1 (zh) |
ES (1) | ES2498797T3 (zh) |
MX (1) | MX2009005222A (zh) |
RU (1) | RU2473551C2 (zh) |
WO (1) | WO2008058448A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011143444A2 (en) * | 2010-05-14 | 2011-11-17 | President And Fellows Of Harvard College | Diphenylbutypiperidine autophagy inducers |
KR101514866B1 (ko) * | 2009-05-14 | 2015-04-24 | 티안진 헤메이 바이오-텍 컴퍼니 리미티드 | 티오펜 유도체 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190093205A (ko) * | 2016-12-21 | 2019-08-08 | 바이오테릭스, 인코포레이티드 | 단백질 표적화에 사용하기 위한 티에노피롤 유도체, 조성물, 방법 및 이의 용도 |
US10570147B2 (en) | 2017-06-13 | 2020-02-25 | Biotheryx, Inc. | Bicyclic compounds and methods of use |
CN116813637A (zh) | 2018-05-02 | 2023-09-29 | 天津合美医药科技有限公司 | 噻吩衍生物的晶型 |
CN116332954A (zh) * | 2021-12-21 | 2023-06-27 | 赣州和美药业股份有限公司 | 噻吩衍生物的制备 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997023457A1 (en) | 1995-12-26 | 1997-07-03 | Celgene Corporation | Imides as pde iii, pde iv and tnf inhibitors |
US20060019928A1 (en) * | 2004-06-30 | 2006-01-26 | James Lin | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
US20060199836A1 (en) * | 2005-03-02 | 2006-09-07 | Fibrogen, Inc. | Novel thienopyridine compounds, and methods of use thereof |
CN1939922A (zh) * | 2005-09-27 | 2007-04-04 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2571723B1 (fr) * | 1984-10-12 | 1988-08-26 | Lipha | Derives de thieno et furo-(2,3-c) pyrroles, procedes de preparation et medicaments les contenant |
FI862513A (fi) * | 1985-07-04 | 1987-01-05 | Chemie Linz Ag | Nya tieno-1,2-tiazolderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska preparat. |
US4732984A (en) * | 1985-10-17 | 1988-03-22 | American Home Products Corporation | Piperazinoisothiazolones with psychotropic activity |
ATA39088A (de) * | 1988-02-18 | 1990-06-15 | Binder Dieter Dr | Basisch substituierte thienoisothiazol-3(2h)-on-1,1-dioxide und ihre pharmazeutisch vertraeglichen salze, verfahren zu ihrer herstellung und ihre verwendung |
DE4023048A1 (de) * | 1990-07-20 | 1992-01-23 | Basf Ag | Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
EP0599697A1 (fr) * | 1992-11-24 | 1994-06-01 | Synthelabo | Dérivés de pyrrole, leur préparation et leur application en thérapeutique |
US5334596A (en) * | 1993-05-11 | 1994-08-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
DE19858193A1 (de) * | 1998-12-17 | 2000-06-21 | Aventis Cropscience Gmbh | 4-Trifluormethyl-3-oxadiazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
WO1999046267A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
CA2401711C (en) * | 2000-02-29 | 2008-06-03 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
CN100383139C (zh) * | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2,6-二酮衍生物 |
PE20071241A1 (es) * | 2006-01-17 | 2008-01-14 | Schering Corp | Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios |
-
2006
- 2006-11-15 CN CN200610129421A patent/CN101186612B/zh active Active
-
2007
- 2007-10-16 MX MX2009005222A patent/MX2009005222A/es not_active Application Discontinuation
- 2007-10-16 BR BRPI0716005-4A2A patent/BRPI0716005A2/pt not_active IP Right Cessation
- 2007-10-16 US US12/514,672 patent/US8466191B2/en active Active
- 2007-10-16 WO PCT/CN2007/002965 patent/WO2008058448A1/zh active Application Filing
- 2007-10-16 KR KR1020097012187A patent/KR20090086592A/ko not_active Application Discontinuation
- 2007-10-16 RU RU2009121676/04A patent/RU2473551C2/ru not_active IP Right Cessation
- 2007-10-16 JP JP2009536582A patent/JP5491863B2/ja active Active
- 2007-10-16 AU AU2007321636A patent/AU2007321636A1/en not_active Abandoned
- 2007-10-16 EP EP07816579.2A patent/EP2083011B1/en active Active
- 2007-10-16 ES ES07816579.2T patent/ES2498797T3/es active Active
- 2007-10-16 CA CA002669357A patent/CA2669357A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997023457A1 (en) | 1995-12-26 | 1997-07-03 | Celgene Corporation | Imides as pde iii, pde iv and tnf inhibitors |
US20060019928A1 (en) * | 2004-06-30 | 2006-01-26 | James Lin | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
US20060199836A1 (en) * | 2005-03-02 | 2006-09-07 | Fibrogen, Inc. | Novel thienopyridine compounds, and methods of use thereof |
CN1939922A (zh) * | 2005-09-27 | 2007-04-04 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物 |
Non-Patent Citations (27)
Title |
---|
ABBOUD H.E., KIDNEY INT., vol. 43, 1993, pages 252 - 267 |
BAUGHMAN ET AL., J. LAB. CLIN. MED., vol. 115, no. 1, 1990, pages 36 - 42 |
BETOLINNI ET AL., NATURE, vol. 319, 1986, pages 516 - 8 |
BIOORG. MED. CHEM. LETT., vol. 8, 1998, pages 2669 |
BISSONNETTE ET AL., INFLAMMATION, vol. 13, no. 3, 1989, pages 329 - 339 |
CALCI. TISSUE INT. (US, vol. 46, 1990, pages S3 - 10 |
CAMMUSI G. ET AL., KIDNEY INT., vol. 43, no. 39, pages 32 - 36 |
DEZUBE ET AL., LAUCET, vol. 335, no. 8690, 1990, pages 662 |
DUH ET AL., PROC. NAT. ACAD. SCI., vol. 86, 1989, pages 5974 - 8 |
EGIDO J. ET AL., KIDNEY INT., vol. 43, no. 39, 1993, pages 59 - 64 |
GRAU ET AL., N. ENGL. J. MED., vol. 320, no. 24, 1989, pages 1586 - 91 |
HINSHAW ET AL., CIRC SHOCK, vol. 30, 1990, pages 279 - 92 |
HOLLER ET AL., BLOOD, vol. 75, no. 4, 1990, pages 1011 - 1016 |
J. MED. CHEM., vol. 39, 1996, pages 3238 |
JOURNAL OF QIQIHAR MEDICAL COLLEG, vol. 22, no. 10, 2001, pages 1119 - 1120 |
LOME; CHENG, DRUGS OF THE FUTUNE, vol. 17, no. 9, 1992, pages 799 - 807 |
MILLAR ET AL.: "Adult Respiratory Distress Syndrome (ARDS", LAUCET, vol. 2, no. 8665, 1989, pages 712 - 714 |
MONTO ET AL., BLOOD, vol. 79, 1990, pages 2670 |
PIGNET ET AL., NATURE, vol. 344, 1990, pages 245 - 7 |
POLL ET AL., AIDS RES. HUMAN RETROVIRUS, 1992, pages 191 - 197 |
POLL ET AL., PROC. NAT. ACAD. SCI., vol. 87, 1990, pages 782 - 5 |
See also references of EP2083011A4 |
TRACEY ET AL.: "Endotoxaemia and/or toxic shock syndrome", NATURE, vol. 330, 1987, pages 662 - 4 |
UADDER ET AL., PNAS, vol. 87, 1990, pages 2643 - 6 |
WANG XIN ET AL., CHINESE JOURNAL OF INFECTIOUS DISEASES, vol. 15, no. 2, 1997, pages 85 - 88 |
YOSHIOKA ET AL., HEPATOLOGY, vol. 10, 1989, pages 769 - 777 |
YU YANYAN, CHINESE JOURNAL OF INTERNAL MEDICINE, vol. 35, 1996, pages 28 - 31 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101514866B1 (ko) * | 2009-05-14 | 2015-04-24 | 티안진 헤메이 바이오-텍 컴퍼니 리미티드 | 티오펜 유도체 |
WO2011143444A2 (en) * | 2010-05-14 | 2011-11-17 | President And Fellows Of Harvard College | Diphenylbutypiperidine autophagy inducers |
WO2011143444A3 (en) * | 2010-05-14 | 2012-04-05 | President And Fellows Of Harvard College | Diphenylbutypiperidine autophagy inducers |
Also Published As
Publication number | Publication date |
---|---|
RU2473551C2 (ru) | 2013-01-27 |
CN101186612B (zh) | 2012-10-03 |
JP5491863B2 (ja) | 2014-05-14 |
AU2007321636A1 (en) | 2008-05-22 |
US8466191B2 (en) | 2013-06-18 |
JP2010509377A (ja) | 2010-03-25 |
EP2083011A4 (en) | 2011-03-09 |
BRPI0716005A2 (pt) | 2014-05-13 |
EP2083011A1 (en) | 2009-07-29 |
RU2009121676A (ru) | 2010-12-20 |
MX2009005222A (es) | 2009-07-02 |
EP2083011B1 (en) | 2014-06-04 |
KR20090086592A (ko) | 2009-08-13 |
CA2669357A1 (en) | 2008-05-22 |
ES2498797T3 (es) | 2014-09-25 |
CN101186612A (zh) | 2008-05-28 |
US20100179189A1 (en) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10406147B2 (en) | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | |
AU2006296912B2 (en) | 5H-thieno [3,4-c] pyrrole-4, 6-dione derivatives against cell releasing tumor necrosis factor | |
WO2008058448A1 (fr) | Dérivés de pyrroline agissant contre les cellules libérant le facteur de nécrose tumorale, procédés de préparation et utilisations associés | |
JP5852269B2 (ja) | Mogat−2阻害剤として有用な新規モルホリニル誘導体 | |
JP2007145819A (ja) | 医薬組成物 | |
WO2008058449A1 (fr) | Dérivés de pyrroline-2-one utilisés contre le facteur de nécrose tumorale à libération cellulaire, procédés de préparation et utilisations de ceux-ci | |
WO2002098839A1 (fr) | Biphenylcarboxamides et procede de preparation de ceux-ci | |
WO2002074296A1 (fr) | Medicaments contre le cancer solide contenant des derives de l'acide hydroxamique comme ingredient actif | |
WO2021121420A1 (zh) | 苯并吡唑类化合物及其中间体、制备方法和应用 | |
WO1999067235A1 (fr) | Composes cycliques a cinq elements | |
EP2459532A1 (en) | Antitumor 1,2-diphenylpyrrole compounds and their preparation process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07816579 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007816579 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009536582 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2669357 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/005222 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007321636 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3863/DELNP/2009 Country of ref document: IN Ref document number: 1020097012187 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2009121676 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2007321636 Country of ref document: AU Date of ref document: 20071016 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12514672 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0716005 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090515 |